Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Short Interest Update

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 262,477 shares, a decline of 51.7% from the July 15th total of 542,999 shares. Based on an average daily trading volume, of 793,416 shares, the short-interest ratio is currently 0.3 days. Approximately 3.0% of the company’s stock are short sold.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TVRD. Schonfeld Strategic Advisors LLC bought a new position in Tvardi Therapeutics during the 3rd quarter valued at $746,000. Geode Capital Management LLC lifted its holdings in shares of Tvardi Therapeutics by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after buying an additional 9,214 shares during the period. State Street Corp lifted its holdings in shares of Tvardi Therapeutics by 83.7% in the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after buying an additional 52,637 shares during the period. Squarepoint Ops LLC boosted its stake in Tvardi Therapeutics by 534.3% during the fourth quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after buying an additional 43,619 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in Tvardi Therapeutics during the second quarter valued at about $92,000. 44.66% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on TVRD. BTIG Research decreased their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 8th. Finally, Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Stock Down 0.8%

TVRD stock traded down $0.01 during midday trading on Tuesday, reaching $1.85. The company had a trading volume of 9,451 shares, compared to its average volume of 967,049. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The firm has a market capitalization of $17.32 million, a PE ratio of -0.66 and a beta of 0.39. The stock has a 50 day moving average price of $2.47 and a 200 day moving average price of $3.16.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Research analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.